文献速递妇科

卵巢癌CT复发模式的预后价值

Prognostic value of radiological recurrence patterns in ovarian cancer.
PubMed 文献 · Gynecol Oncol · 2020-03-11

本研究对89例上皮性卵巢癌复发患者进行CT复发模式系统再评估,分为腹膜为主、血行和淋巴复发三组。淋巴复发患者中位生存52.9个月,优于腹膜复发25.8个月和血行复发27.6个月。淋巴复发模式为独立良好预后因素,手术彻底性与复发时间相关。

要点

  • 淋巴复发模式中位生存52.9个月,优于腹膜和血行复发
  • 淋巴复发模式HR 0.42(95%CI 0.21-0.85),为良好预后因素
  • 手术彻底性影响复发时间,完全减灭组中位复发时间19.5个月

核心结论

  • 淋巴为主复发模式的上皮性卵巢癌患者生存期长于腹膜或血行复发患者。
  • 手术彻底性与复发时间相关,复发模式分类有助于向患者交代复发时预后。

研究设计与样本

  • 对CT扫描按预设解剖部位系统再评估肿瘤存在情况,采用Cox比例风险分析检验复发模式对生存的影响。

主要发现

  • 腹膜为主复发(n=62)中位生存25.8个月(95%CI 18.4-33.2)。
  • 血行复发(n=13)中位生存27.6个月(95%CI 18.5-36.6)。
  • 淋巴复发(n=14)中位生存52.9个月(95%CI 42.1-63.7)。
  • 单因素Cox回归识别预后因素:淋巴复发模式HR 0.42(95%CI 0.21-0.85),诊断时腹水HR 2.35(95%CI 1.46-3.79),初次手术残留肿瘤HR 2.16(95%CI 1.36-3.44),FIGO分期(I-IIIB)HR 0.59(95%CI 0.33-1.06)。
  • 完全减灭术后中位复发时间19.5个月,残留≤1 cm者13.1个月,残留>1 cm者8.2个月(P < 0.001)。

关键数值与推荐

  • 淋巴复发模式HR 0.42(95%CI 0.21-0.85)。
  • 诊断时腹水HR 2.35(95%CI 1.46-3.79)。
  • 初次手术残留肿瘤HR 2.16(95%CI 1.36-3.44)。
  • FIGO分期I-IIIB HR 0.59(95%CI 0.33-1.06)。
  • 完全减灭术后中位复发时间19.5个月,残留≤1 cm者13.1个月,残留>1 cm者8.2个月(P < 0.001)。

临床怎么用

  • 复发时依据CT复发模式(腹膜为主、血行或淋巴)可辅助判断预后并向患者交代。
  • 淋巴复发模式提示生存期较长,腹膜或血行复发提示预后相对较差。
  • 初次手术彻底性影响复发时间,完全减灭者复发时间较晚。

局限性

  • 单中心回顾性研究,样本量89例,部分复发模式亚组样本量较小。
  • 原文未报告多因素Cox回归分析结果。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

OBJECTIVE: To study the prognostic value of CT assessed recurrence patterns on survival outcomes in women with epithelial ovarian cancer. METHODS: CT scans were systematically re-evaluated on predefined anatomical sites for the presence of tumor in all 89 patients diagnosed with epithelial ovarian cancer between January 2008 and December 2013 who underwent cytoreductive surgery at our institution and developed a recurrence. A Cox proportional hazard analysis was used to test the effect of recurrence patterns on survival. RESULTS: The median survival time for patients grouped as predominantly intraperitoneal (n = 62), hematogenous (n = 13) or lymphatic (n = 14) recurrence was 25.8 (95% CI 18.4-33.2), 27.6 (95% CI 18.5-36.6) and 52.9 months (95% CI 42.1-63.7), respectively. Univariate Cox regression analysis identified the following prognostic factors: lymphatic recurrence pattern (HR 0.42, 95% CI 0.21-0.85), ascites at diagnosis (HR 2.35, 95% CI 1.46-3.79), residual tumor at initial surgery (HR 2.16, 95% CI 1.36-3.44) and FIGO stage (I-IIIB: HR 0.59, 95% CI 0.33-1.06). The median time to recurrence was 19.5 month for patients after complete debulking surgery, 13.1 months for patients with residual disease ≤1 cm and 8.2 months for patients with residual disease >1 cm after surgery (P < 0.001). No differences in recurrence patterns between patients with complete and incomplete surgery were found. CONCLUSIONS: Prolonged survival rates were found in ovarian cancer patients with a predominantly lymphatic recurrence compared to patients with a predominantly peritoneal or hematogenous recurrence. Completeness of surgery was associated with time to recurrence. Classification of recurrence patterns can help counsel patients on their prognosis at the time of recurrence.

来源:Gynecol Oncol,查看原文。版权归原作者所有。

引用

  1. Roze JF, Veldhuis WB, Hoogendam JP, et al. Prognostic value of radiological recurrence patterns in ovarian cancer. Gynecol Oncol. 2020. PMID: 32171567. doi:10.1016/j.ygyno.2020.03.003

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。